A Phase 1, Open-label, Multicenter, Single-dose Study to Assess the Pharmacokinetics of CC-90001 in Subjects With Mild, Moderate, and Severe Hepatic Impairment Compared With Healthy Subjects
Latest Information Update: 04 Nov 2021
At a glance
- Drugs BMS 986360 (Primary)
- Indications Idiopathic pulmonary fibrosis; Non-alcoholic steatohepatitis
- Focus Pharmacokinetics
- Sponsors Celgene Corporation
- 26 Jun 2021 Results assessing pharmacokinetics, safety, and tolerability of CC-90001 in patients with hepatic impairment, presented at The International Liver Congress 2021.
- 23 Jul 2020 Status changed from not yet recruiting to completed.
- 22 Nov 2018 New trial record